Vakt ® is a whole virus vaccines against trenbolone enanthate cycle A virus obtained by culturing diploid cells in MRS-5 human fibroblasts, its subsequent purification, inactivation with formalin and adsorbed on aluminum hydroxide.
Active ingredient: protein is trenbolone enanthate cycle A virus ~50 U / ml.
Inactive ingredients:. Aluminium hydroxide 0.45 mg / ml – sorbent, sodium borate – Stabilizer pH, traces of formaldehyde
preservatives and contains no antibiotics.
Prevention of trenbolone enanthate cycle A from the age of two.
DOSAGE AND METHOD OF APPLICATION
immunization course consists of 2 vaccinations -. Vaccination and re-vaccination
After vaccination, the immune system develops after 14 days at 95-97% of vaccinees. Revaccination preserves immunity for 6 years (time of observation).Children / teenagers persons aged 2 to 17 years old on the date selected by single dose of 0.5 ml (~25 units), revaccination is carried out through 6-18 months at a dose of 0 5 ml (~25 units). Adult Persons aged 18 years or older on the date selected by single dose of 1.0 ml (~50 units), revaccination is carried out after 6 months at a dose of 1.0 ml (~50 units). Waqt is intended for intramuscular injection. The preferred injection site is the deltoid muscle. NEVER injected vaccine intravenously. Intradermally or subcutaneously. The vaccine is produced in the form of a ready to use and does not require additional dilution. Before you set the dose in the syringe vaccine vial should be shaken vigorously. This should form a translucent white suspension without foreign particulate matter. In order to prevent the transmission of infectious diseases for each of the graft is necessary to use a separate sterile syringe and needle.
Hypersensitivity to any component of the vaccine.
Severe reaction (temperature above 40 ° C, swelling, redness more than 8 cm) or immediate type allergic reaction to the first administration of the drug. Routine vaccination is delayed until the acute disease (exacerbation of chronic disease).
Patients who after the first injection Waqt develop symptoms that suggest the presence of hypersensitivity should not receive further injections of the vaccine (sm. CONTRAINDICATIONS).
The expected immune response may not develop if Waqt is used in patients with malignancies or receiving immunosuppressive drugs, as well as in persons with impaired immune systems.
Waqt does not prevent trenbolone enanthate cycle caused by other pathogens, in addition to trenbolone enanthate cycle A.
in individuals vaccinated in the incubation period of trenbolone enanthate cycle a (duration of 20-50 days), vaccination may not prevent trenbolone enanthate cycle A.
Like upon administration of any other vaccine should be ready required therapeutic agents, including adrenaline, for immediate use in the event of an anaphylactic or anaphylactoid reactions.
As with the introduction of any other vaccine Vakt application can cause the development of immunity not all vaccinees.
Study Waqt effects on reproductive function in animals have been conducted. It is also unknown whether Waqt can when administered to pregnant women cause fetal damage or affect reproductive capacity.
It is not known whether there is Waqt excretion during lactation. Because many drugs are excreted in human milk, caution should be exercised in the appointment of vaccine administration to nursing mothers
USE IN PEDIATRICS
shown that Waqt well tolerated and highly immunogenic in children older than 2 years. The recommended vaccination schedule cm. In section “Dosage”.
The safety and efficacy Waqt in children under the age of 2 years has not been established.
INTERACTION WITH OTHER DRUGS The use with other vaccines. Waqt can be used simultaneously with the yellow fever vaccine and inactivated typhoid vaccine. The data allow to recommend the simultaneous use of Waqt with other vaccines are not currently available. The use of a human immunoglobulin. In the case of trenbolone enanthate cycle A after contact with the pathogen or, if necessary rapid and long-term prophylaxis, for example, those traveling to endemic hot areas may be administered simultaneously Vakt immunoglobulin separate syringes at different sites.
During clinical trials, no serious side effects associated with the use of vaccines was observed. Children / adolescents aged 2 to 17 years. In the pooled clinical studies conducted on 2595 healthy children and adolescents (including placebo controlled study on 1037 participants) who received one (~25 units) or more doses of trenbolone enanthate cycle a vaccine, within the first 5 days after vaccination actively detects the presence of temperature reactions and complaints of discomfort at the injection site, and for 14 days – emergence the systemic nature of the complaints. Below are details on the frequency of complaints registered in one or more percent of the vaccinated, regardless of their causes. injection site reactions (generally mild and transient) Pain (18.7%), pain when touched (16, 8%), hot flashes (8.6%), flushing (7.5%), edema (7.3%), subcutaneous hemorrhage (1.3%). GENERAL REACTION fever – the temperature in the mouth ≥38,8 ° C (3.1%), abdominal pain (1.6%). The digestive system Diarrhea (1.0%), vomiting (1.0%). NERVOUS SYSTEM / MIND Headache (2.3%). rESPIRATORY SYSTEM Pharyngitis (1.5%), upper respiratory tract infection (1.1%), cough (1.0%). lABORATORY DATA on laboratory abnormalities reported rarely. These included isolated cases of elevated liver enzymes, eosinophilia, and increase the protein content in the urine. Adults aged 18 years and older. In combined clinical studies conducted on 1529 healthy adults who received one (~50 units) or more doses trenbolone enanthate cycle a vaccine, within the first 5 days after vaccination actively detects the presence of temperature reactions and complaints of discomfort at the injection site, and for 14 days – the emergence of the systemic nature of the complaints. Below are details on the frequency of complaints registered in one or more percent of the vaccinated, regardless of their causes. Injection site reactions (generally mild and transient) Tenderness to the touch (52.6%), pain (51.1%), hot flashes (17.3%), edema (13.6%), flushing (12.9%), subcutaneous hemorrhage (1.5%), pain / burning (1.2%). REACTIONS General weakness / fatigue ( 3.9%), fever – the temperature in the mouth ≥38,8 ° C (1.3%), abdominal pain (1.3%). The digestive system Diarrhea (2.4%), nausea (2.3 %). musculoskeletal System Myalgia (2.0%), pain in the hands (1.3%), back pain (1.1%), muscle stiffness (1.0%). NERVOUS SYSTEM / MIND Headache (16.1%).rESPIRATORY SYSTEM Pharyngitis (2.7%), upper respiratory tract infection (2.8%), nasal congestion (1.1%). genitourinary system menstruation Violation (1.1%). Local and / or systemic hypersensitivity reactions (pruritus, urticaria, rash), regardless of their causes were detected in less than 1% of cases. As with any vaccine, there is a possibility that the application of Waqt in a very large population may reveal adverse reactions that We were not observed in clinical trials. Running low dose t3 clen cycle trying to lose bodyfat isn’t a real hot idea imo.